Synovial Sarcoma Therapeutics Pipeline Analysis, Volume Analysis, Segments, Value Share and Key Trends

 The study analysed that the Synovialsarcoma pipeline comprises of 22 drug candidates in different stages of development. Synovial sarcoma is rare type of cancer and approximately one to three people in one million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect a person at any age. Synovial sarcoma is more common in males, and the male to female ratio of the disease stands at 12 males for every 10 females. Various new therapies and advanced technologies are driving the growth of Synovial sarcoma pipeline.

Many technologies such as REOLYSIN technology, ZVex and GLAAS technology, Laser Micro-beam Microdissection are being developed that can bring the innovative treatment, which can control the progression of Synovial sarcoma.  ZVex and GLAAS are complementary discovery platforms designed to activate and expand the immune system’s natural ability to create tumour-specific cytotoxic T cells (CTLs) in vivo.

Download Sample of This Research Report:  https://www.psmarketresearch.com/market-analysis/synovial-sarcoma-therapeutics-pipeline-analysis/report-sample

The combination of novel drugs against different organs as well as combination of drugs with biological and biochemical agents may further enhance the treatment quality.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=synovial-sarcoma-therapeutics-pipeline-analysis

The research also found that various companies have collaborated for the development of Synovial sarcoma pipeline. In February 2014, Pfizer Inc. (Pfizer) and Merck & Co., Inc. (Merck) agreed to explore the therapeutic potential of Merck’s investigational anti-PD-1 therapy, MK-3475, in combination with two of the Pfizer’s oncology assets.

Some of the key players developing drugs for Synovial sarcoma include Takara Bio Inc., Oncolytics Biotech Inc., Accuronix Therapeutics, Inc., Cue Biopharma, Inc. and others.

Synovial sarcoma Pipeline Analysis

·         By Phase

·         By Route of Administration

·         By Molecule Type

·         By Company

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Synovial Sarcoma Exhibits Emerging Pipeline with 22 Drug Candidates

The study analysed that the Synovial sarcoma pipeline comprises of 22 drug candidates in different stages of development. Synovial sarcoma is rare type of cancer and approximately one to three people in one million people are diagnosed with synovial sarcoma every year, globally. The disease occurs frequently in young adults; however, the disease can affect...

Read More

IgA Nephropathy Pipeline to Witness Various Collaborations in the Coming Years

The study analyzed that the IgAnephropathy pipeline comprises of 12 drug candidates in different stages of development. IgA nephropathy, also known as Berger’s disease, is a kidney disorder that occurs when IgA antibody gets settled in the kidneys. This leads to inflammation that with time hinders the kidney’s ability to filter wastes from blood.

IgA nephropathy is a silent disease in its early stages with no symptoms. But the most common symptoms that are usually observed are proteinuria and hematuria. IgA nephropathy does not have a specific treatment, and the only treatment available is to delay or prevent end stage renal disease (ESRD). Therefore, combination therapies are being used to slow down the rate of proteinuria and hematuria and the use of various targets including a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS) is expected to provide an effective and concrete treatment for the disease, with latest technological advancements further adding to the pipeline growth.

Download Report Sample at: https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis/report-sample

Pharmalink AB is using TARGIT drug delivery technology platform for the development of Budesonide for IgA nephropathy. The TARGIT technology is based on the application of a combination of enteric polymers onto injection-moulded starch capsules, for the targeted delivery of drugs to specific regions of the large intestine. 

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=iga-nephropathy-pipeline-analysis

The research finds that different companies have collaborated for the development of IgA nephropathy pipeline. In October 2012, Pharmalink AB entered into a contract with Patheon Inc. for manufacturing of Nefecon.

Some of the key players developing drugs for IgA nephropathy include Mallinckrodt plc, Merck KGaA, Anthera Pharmaceuticals, Inc. and others.

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Sjögren’s Syndrome Market Insights in Pathogenic, Clinical Trails and Therapeutic Pipeline Analysis

The study analyzed that Sjögren’s syndromepipeline comprises of approximately 42 drug candidates in different stages of development. Sjögren’s syndrome is a chronic inflammatory disease, which leads to infiltration of lacrimal and salivary glands. It is mostly associated with sicca symptoms, which include dry eyes (xeropthalmia) and dry mouth (xerostomia).

It is also associated with other autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. The treatment approaches for this disease mostly include monoclonal antibodies and small molecules, which are being developed to target and reduce the inflammatory mediators. Clinical presentation can vary considerably from relatively mild sicca symptoms, fatigue and arthralgia to severe systemic symptoms such as glomerulonephritis, vasculitis and a host of neurological manifestations.

Download Free Sample of This Research Report:  https://www.psmarketresearch.com/market-analysis/sjogrens-syndrome-therapeutics-pipeline-analysis/report-sample

The positive results of the drug candidates are speeding up the drug development process for Sjögren’s syndrome. In August 2016, Aldeyra Therapeutics, Inc. presented the positive Phase II results of NS2, a 1% dermatologic cream under Phase II stage of development for Sjögren's syndrome. Six of six (100%) subjects treated with NS2 improved over the course of therapy as assessed by central review, and the improvement was greater than that observed among vehicle-treated patients (p < 0.05).

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=sjogrens-syndrome-therapeutics-pipeline-analysis

The research found that different companies have collaborated for the development of Sjögren’s syndrome.

Some of the key players developing drugs for Sjögren’s syndrome include Kissei Pharmaceutical Co., Ltd., UCB Group, Bristol-Myers Squibb Company and others.

Sjögren’s Syndrome Pipeline Analysis

·         By Phase

·         By Route of Administration

·         By Molecule Type

·         By Company

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More

Ulcerative Colitis Therapeutics Pipeline Analysis, 2017 - Clinical Trials, Results, Patent, Designation, Collaboration and Other Developments

The ulcerative colitis pipeline analysis report covers approximately 89 drug candidates in different stages of development.

Ulcerative colitis is a chronic inflammatory disease, which basically affect colonic mucosa. The main identified symptoms of the disease are bloody diarrhea, abdominal cramps and fatigue. Some of the other symptoms include, fever, vomiting, anorexia, abdominal distension and bloating. The treatment approaches to this disease mostly include the use of small molecules and monoclonal antibodies, which are being developed to target and reduce the inflammatory mediators.

Download Free Sample of This Research Report:  https://www.psmarketresearch.com/market-analysis/ulcerative-colitis-pipeline-analysis/report-sample

The research found that different companies are engaged in the collaboration for ulcerative colitis. In June, 2015 Lycera Corp. and Celgene Corporation collaborated for the development of Lycera Corp. drug candidate for the treatment of ulcerative colitis. Celgene obtained the exclusive right to acquire Lycera upon conclusion of the option period or achievement by Lycera of pre-specified clinical milestones. During the option period, Lycera retained full control of its research and development programs.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=ulcerative-colitis-pipeline-analysis

Some of the key players developing ulcerative colitis therapeutics include EA Pharma Co., Ltd., Celgene Corporation, InDex Pharmaceuticals AB and others.

Ulcerative Colitis Pipeline Analysis

• By Phase
• By Route of Administration
• By Molecule Type
• By Company

Contact:

Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +18887787886 (USA/Canada)

Email: enquiry@psmarketresearch.com

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook

Read More